Since raloxifene, NAC and losartan upregulate endoglin in conjunction with a decrease in the active TGF-β1 protein, we explored endoglin and TGF-β1 mRNA expression in fibroblasts from the same three patients (Figure 2A), as well as that of some representative RDEB biomarkers like periostin, thrombospondin (TSP-1), Transforming Growth Factor Inhibitor (TGFI), Tenascin C and IL-6, the latter the main inflammatory biomarker altered in different models of RDEB [9,21] (Figure 2A). Here, TGFB1 is linked to recessive dystrophic epidermolysis bullosa.